BRIEF-Exelixis says phase 2 trial met primary endpoint for advanced renal cell carcinoma
May 23, 2016 at 09:18 AM EDT
* Announces results from randomized phase 2 trial cabosun demonstrate cabozantinib significantly improved progression free survival versus sunitinib in previously untreated advanced renal cell carcinoma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)